With positive Phase 1 results for the metabolic disorder drug MZE782, Maze Therapeutics plans to advance the small molecule to Phase 2 tests in phenylketonuria and chronic kidney disease. Following the data readout, Maze raised $150 million in a private placement.
The post Maze Therapeutics Drug Shows Potential to Top Asset Acquired by Otsuka for $800M appeared first on MedCity News.
